Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04495816 · ClinicalTrials.gov registry record · Phase 2
COVID-19 Anosmia Study
A Phase 2 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 2
- Development phase
- 139
- Enrollment target
NCT04495816 is a Phase 2 study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 139 participants.
The verdict
NCT04495816, a Phase 2 study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 139 participants
- Enrollment target
Study Summary
To capture the natural history of COVID-19 associated olfactory dysfunction as measured by two patient reported outcome measures (SNOT-22, QOD-NS) and a 6-week BSIT with a comparison to an intervention arm receiving daily omega-3 supplements.
Interventions
- DRUG Omega-3 Fatty Acid Supplement
- DRUG Placebo/Control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2020-07-15 |
| Est. Completion | 2021-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04495816
The ClinicalTrials.gov registry entry for NCT04495816 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Omega-3 Fatty Acid Supplement is the first listed.
NCT04495816 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04495816 about?
NCT04495816 is a clinical study titled "COVID-19 Anosmia Study". To capture the natural history of COVID-19 associated olfactory dysfunction as measured by two patient reported outcome measures (SNOT-22, QOD-NS) and a 6-week BSIT with a comparison to an intervention arm receiving daily omega-3 supplements.
What is the current status of trial NCT04495816?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 139 participants. The study started on 2020-07-15. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT04495816?
The interventions under investigation include: Omega-3 Fatty Acid Supplement (DRUG), Placebo/Control (DRUG).
Who is sponsoring clinical trial NCT04495816?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.